The role of eIF4E as a key player in oncogenic transformation is supported by previous studies; phosphorylation of eIF4E occurs in breast cancer cells following exposure to growth factors and chemotherapy while its de-activation inhibited proliferation of lung and prostate cancer cells [57,58,59]. This evidence concerns the gene EIF4E and prostate cancer.